Dalton transactions (Cambridge, England : 2003) · 2026
Structurally characterized Ni(II) complex exhibiting potent anti-Candida activity: biomolecular interaction mechanism and in silico ADMET insights.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Saha Alipe, Maity Ribhu, Dhara Gurupada, Brandao Paula, Pattanayak Satyajit, Maity Tithi, Sarkar Keka, Samanta Bidhan Chandra
Аннотация
The current study reports the synthesis, structural interpretation, biomolecular interaction, and antifungal appraisal of a Ni(II) Schiff base complex demonstrating effective activity against Candida albicans. The complex, formulated as [Ni(L)2], features a NiN4O2 coordination environment and was synthesized using the ligand L, [4-bromo-2-((3-(methylamino)propylimino)methyl)phenol], derived from the condensation of 5-bromo-2-hydroxybenzaldehyde with N-methylpropane-1,3-diamine, followed by complexation with nickel(II) chloride in methanol. The complex was comprehensively characterized by FTIR, 1H NMR, ESI-MS, and single-crystal X-ray diffraction analyses. Crystallographic studies reveal that the complex crystallizes in a monoclinic system with a slightly distorted octahedral geometry around the Ni(II) center. UV-Vis and fluorescence spectroscopic investigations indicate strong CT-DNA binding via a groove mode of binding and static quenching interactions with bovine serum albumin (BSA). Moreover, in silico ADMET analysis predicts favourable pharmacokinetic properties, validating the experimental findings that reveal prominent antifungal efficiency of the complex against fluconazole-resistant Candida albicans. Besides, the in silico findings with experimental cytotoxicity evaluation using a mammalian cell model (HEK-293T), provide direct biological evidence of biocompatibility at functionally relevant concentrations. This experimental validation strengthens the overall safety assessment and mitigates the uncertainty associated with computational ADMET analysis for coordination compounds.